Kodiak Sciences Inc. (NASDAQ:KOD) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCCP), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of the two firms.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences Inc.	N/A	0.00	41.44M	-1.07	0.00
Cyclacel Pharmaceuticals Inc.	N/A	0.00	N/A	-0.63	0.00

Table 1 demonstrates Kodiak Sciences Inc. and Cyclacel Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Kodiak Sciences Inc. and Cyclacel Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences Inc.	0.00%	0%	0%
Cyclacel Pharmaceuticals Inc.	0.00%	0%	0%

Analyst Ratings

The Ratings and Recommendations for Kodiak Sciences Inc. and Cyclacel Pharmaceuticals Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Kodiak Sciences Inc.	0	0	1	3.00
Cyclacel Pharmaceuticals Inc.	0	0	0	0.00

Kodiak Sciences Inc.’s consensus target price is $22.5, while its potential upside is 222.35%.

Insider and Institutional Ownership

Institutional investors owned 48.2% of Kodiak Sciences Inc. shares and 0.69% of Cyclacel Pharmaceuticals Inc. shares. Insiders owned roughly 11.8% of Kodiak Sciences Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Kodiak Sciences Inc.	1.45%	-8.98%	-24.19%	0%	0%	-1.55%
Cyclacel Pharmaceuticals Inc.	-6.79%	-5.95%	-12.73%	-16.85%	-15.11%	-15.52%

For the past year Kodiak Sciences Inc. has stronger performance than Cyclacel Pharmaceuticals Inc.

Summary

Kodiak Sciences Inc. beats on 3 of the 5 factors Cyclacel Pharmaceuticals Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.